NCT06776380 Pubertal Development in Patients with RASopathies
| NCT ID | NCT06776380 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | RASopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-07-25 |
| Primary Completion | 2025-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-07-25 with a primary completion date of 2025-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Retrospective, single-centre, non-profit, observational study on pubertal development in patients with RASopathies. Literature data shows that puberty can be delayed by about 2 years in patients with RASopathies and this has been associated with a reduced peak growth rate. To date, only a few numerically limited case series without molecular characterisation have been published. This descriptive study should improve knowledge of pubertal development and its influence on growth and final stature. The primary aims are to describe the age of onset and progression of pubertal development in the cohort of patients with RASopathies, both male and female, and to describe the influence of pubertal development on statural growth and final stature in the same cohort.
Eligibility Criteria
Inclusion Criteria: * Age at enrollment between 8 and 35 years, extremes included; * Molecularly confirmed clinical diagnosis of RASopathy; * Complete pubertal development; * Obtaining informed consent for participation in the study and processing of personal data. Exclusion Criteria: • None.
Contact & Investigator
Federica Tamburrino, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06776380 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 35 Years, studying RASopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06776380 currently recruiting?
Yes, NCT06776380 is actively recruiting participants. Contact the research team at federica.tamburrino@aosp.bo.it for enrollment information.
Where is the NCT06776380 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06776380 clinical trial?
NCT06776380 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Federica Tamburrino, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 40 participants.